Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 11/20 | 0.72 |
| ▸ | CLK1 | P49759 | 2/20 | 0.57 |
| ▸ | CLK2 | P49760 | 2/20 | 0.57 |
| ▸ | CSNK1D | P48730 | 7/20 | 0.54 |
| ▸ | CSNK1E | P49674 | 7/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486280 | 0.85 | MAP3K5 (0.67) | MAP3K5CSNK1DCSNK1E | |
| SCHEMBL13498815 | 0.85 | MAP3K5 (0.56) | MAP3K5CSNK1DCSNK1E | |
| SCHEMBL3486166 | 0.84 | MAP3K5 (1.00) | MAP3K5CLK1CLK2 | |
| SCHEMBL13498806 | 0.84 | MAP3K5 (0.57) | MAP3K5CSNK1DCSNK1E | |
| SCHEMBL3487219 | 0.83 | CSNK1D (0.56) | MAP3K5CSNK1DCSNK1E | |
| SCHEMBL13498813 | 0.83 | MAP3K5 (0.56) | MAP3K5CSNK1DCSNK1E | |
| SCHEMBL3485613 | 0.83 | MAP3K5 (0.70) | MAP3K5CSNK1DCSNK1E | |
| SCHEMBL12664439 | 0.81 | CSNK1D (0.49) | MAP3K5CLK1CLK2CSNK1DCSNK1E | |
| SCHEMBL13498810 | 0.81 | MAP3K5 (0.56) | MAP3K5CSNK1DCSNK1E | |
| SCHEMBL13498816 | 0.81 | MAP3K5 (0.53) | MAP3K5CSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10251243-A | — | — | None | — | — | JP | disclosed |
| US-8633356-B2 | Method for controlling root parasitic plants | RIKEN (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20100043101-A1 | Method for controlling root parasitic plants | RIKEN | 2010-02-18 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
| JP-H10251243-A | PRODUCTION OF SORGOLACTONE AND ITS STEREOISOMER, SORGOLACTONE STEREOISOMER, TRICYCLIC LACTONE AND GERMINATION INDUCER | KANEBO LTD | 1998-09-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | MAP3K5 42/4885CLK1 2385/4885CLK2 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.